TP53 and breast carcinoma: Our work suggests that the aggressive biology for TP53 mutant ER+ breast cancer continues in the advanced setting, with the association between TP53 mutation and poor outcome in both treatment arms of the PALOMA-3 trial demonstrating consistency of this finding across 2 different treatments and raising the question of considering this subset of breast cancer a distinct clinical entity.